Page last updated: 2024-12-05

toyocamycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Toyocamycin is a nucleoside antibiotic produced by the bacterium Streptomyces toyocaensis. It is structurally similar to adenosine, with a 7-deazaadenine base and a D-ribofuranose sugar. Toyocamycin is a potent inhibitor of DNA polymerase, and has shown antiviral activity against a variety of viruses, including influenza, herpes simplex, and HIV. It has also been investigated for its potential anticancer activity. The compound's unique structure and biological activities have made it a subject of ongoing research. Toyocamycin has been studied as a potential therapeutic agent for various diseases. It has also been used as a tool to understand the mechanisms of DNA replication and transcription. The synthesis of toyocamycin involves a multi-step process, starting from the preparation of the 7-deazaadenine base. The base is then coupled to a D-ribofuranose sugar to produce the final product.'

Toyocamycin: 4-Amino-5-cyano-7-(D-ribofuranosyl)-7H- pyrrolo(2,3-d)pyrimidine. Antibiotic antimetabolite isolated from Streptomyces toyocaensis cultures. It is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

toyocamycin : An N-glycosylpyrrolopyrimidine that is tubercidin in which the hydrogen at position 5 of the pyrrolopyrimidine moiety has been replaced by a cyano group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11824
CHEMBL ID99668
CHEBI ID134606
SCHEMBL ID336095
MeSH IDM0021736
PubMed CID247955
CHEMBL ID102397
SCHEMBL ID6674952
MeSH IDM0021736

Synonyms (82)

Synonym
4-amino-5-cyano-7-(d-ribofuranosyl)-7h-pyrrolo(2,3-d)pyrimidine
a-399-y4
antibiotic e212
nsc 99843
uramycin b
ahygroscopin-b
4-amino-7-beta-d-ribofuranosyl-7h-pyrrolo(2,3-d)pyrimidine-5-carbonitrile
siromycin
brn 0048454
7h-pyrrolo(2,3-d)pyrimidine-5-carbonitrile, 4-amino-7-beta-d-ribofuranosyl-
cyanotubericidin
e-212
antibiotic a-399-y4
CHEMBL99668 ,
4-26-00-01419 (beilstein handbook reference)
l7995c4d7f ,
unii-l7995c4d7f
cid_247955
bdbm50049823
4-amino-7-(3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile(toyocamycin)
4-amino-7-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
ara-toyocamycine
4-amino-7-((2r,3r,4s,5r)-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
4-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrrolo[2,3-d]pyrimidine-5-carbonitrile
{7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile,} 4-amino-7-.beta.-d-ribofuranosyl-
4-amino-7-(3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
vengicide
7-deaza-7-cyanoadenosine
toyocamycin
606-58-6
antibiotic 1037
4-amino-7-beta-d-ribofuranosyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
CHEBI:134606
4-amino-7-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrrolo[2,3-d]pyrimidine-5-carbonitrile
to1 ,
4-amino-7-(beta-d-ribofuranosyl)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
toyocamycin [mi]
SCHEMBL336095
toyocamicin
XOKJUSAYZUAMGJ-WOUKDFQISA-N
3RE4
AKOS027380922
toyocamycin, >=98% (hplc), from streptomyces rimosus
4-amino-7-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
DB13916
HY-103248
CS-0026179
Q27282806
vengicidevengicide
vengicide; toyocamycin
DTXSID801031395
smr001566801
e-212-1
naritheracin
nsc 63701
4-amino-7-pentofuranosyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
NCI60_042246
NCI60_012274
nsc-63701
b181008 ,
mls002702992 ,
NSC63701 ,
NEURO_000027
nsc-99843
b 181008
unamycin b
toyocamycin nucleoside
nsc99843 ,
antibiotic e 212
4-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrrolo[2,3-d]pyrimidine-5-carbonitrile
CHEMBL102397
CCG-102453
4-amino-7-.beta.-d-ribofuranosyl-7h-pyrrolo(2,3-d)pyrimidine-5-carbonitrile
SCHEMBL6674952
XOKJUSAYZUAMGJ-UHFFFAOYSA-N
7h-pyrrolo(2,3-d)pyrimidine-5-carbonitrile, 4-amino-7-.beta.-d-ribofuranosyl-
4-amino-5-cyano-7-(beta-d-ribofuranosyl)pyrrolo[2,3-d]pyrimidine
FT-0773001
HMS3872J03
A936319
F82140
DTXSID90871786

Research Excerpts

Overview

Toyocamycin is a nucleoside analog. It increased the p16 mRNA level in human normal fibroblasts or synovial cells as assessed by Northern blot hybridization or real time RT-PCR.

ExcerptReferenceRelevance
"Toyocamycin (TM) is an adenosine-analog antibiotic isolated from Streptomyces toyocaensis. "( Concentrative Nucleoside Transporter, CNT, Results in Selective Toxicity of Toyocamycin against Candida albicans.
Azuma, M; Nerome, S; Ojima, Y; Tanibata, Y; Yokota, N, 2022
)
2.39
"Toyocamycin is a member of the nucleoside antibiotic family and has been recognized as a promising fungicide for the control of plant diseases. "( Substantial improvement of toyocamycin production in Streptomyces diastatochromogenes by cumulative drug-resistance mutations.
Cao, ZY; Ochi, K; Shentu, XP; Tang, G; Xiao, Y; Yu, XP, 2018
)
2.22
"Toyocamycin is a nucleoside analog, and it increased the p16 mRNA level in human normal fibroblasts or synovial cells as assessed by Northern blot hybridization or real time RT-PCR."( Induction of p16/INK4a gene expression and cellular senescence by toyocamycin.
Egawa, K; Kunimoto, S; Kurihara, Y; Nose, K; Takeuchi, T, 2002
)
1.27
"Toyocamycin is an antitumor antibiotic which has a pyrrolo[2,3-D]pyrimidine aglycone with a -CN substituent on the 5-carbon. "( Structural and functional relationships of toyocamycin on NPM-translocation.
Chan, PK; Finch, RA; Revankar, GR, 1997
)
2

Effects

ExcerptReferenceRelevance
"Toyocamycin has antibiotic, antiviral and cytotoxic properties, and is known to inhibit ribosome biogenesis, specifically the maturation of 40 S."( Interaction of Rio1 kinase with toyocamycin reveals a conformational switch that controls oligomeric state and catalytic activity.
Kiburu, IN; LaRonde-LeBlanc, N, 2012
)
1.38

Actions

ExcerptReferenceRelevance
"Toyocamycin does not inhibit the synthesis of 16 S premessager RNA for globin, nor does it prevent splicing for mature 9 S globin messenger."( [Effect of a selective inhibitor of ribosomal RNA on induction of differentiation of the Friend cell].
Hamelin, R; Madaule, P; Tavitian, A, 1982
)
0.99

Treatment

ExcerptReferenceRelevance
"Toyocamycin treatment resulted in reduced cell viability of PC-3 cells, but not of non-malignant RWPE-1 cells."( Toyocamycin induces apoptosis via the crosstalk between reactive oxygen species and p38/ERK MAPKs signaling pathway in human prostate cancer PC-3 cells.
Ahn, SC; Choi, HD; Kim, KY; Kim, SH; Kim, YW; Nam, HW; Park, SG; Seo, YK; Yu, SN, 2017
)
2.62

Compound-Compound Interactions

ExcerptReferenceRelevance
" Mice receiving the combination of tubercidin (or nebularine) plus NBMPR-P or dilazep, as well as those that survived the combination with dipyridamole, appeared healthy and were found to have normal size livers and spleens."( Treatment of schistosomiasis by purine nucleoside analogues in combination with nucleoside transport inhibitors.
Cha, S; el Kouni, MH; Messier, NJ, 1987
)
0.27
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antimetaboliteA substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
N-glycosylpyrrolopyrimidine
nitrileA compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it.
ribonucleosideAny nucleoside where the sugar component is D-ribose.
antibiotic antifungal agentHeteroorganic entities that are microbial metabolites (or compounds derived from them) which have significant antifungal properties.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency28.18380.01846.806014.1254AID624417
TDP1 proteinHomo sapiens (human)Potency0.01460.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency0.11500.00527.809829.0929AID588855; AID720534; AID720536; AID720537
67.9K proteinVaccinia virusPotency0.00670.00018.4406100.0000AID720579; AID720580
IDH1Homo sapiens (human)Potency0.14580.005210.865235.4813AID686970
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Rattus norvegicus (Norway rat)IC50 (µMol)3,235,940.00000.00020.552110.0000AID34006
Adenosine receptor A3Rattus norvegicus (Norway rat)IC50 (µMol)3,235,940.00000.00070.03740.0957AID34006
Adenosine receptor A2bRattus norvegicus (Norway rat)IC50 (µMol)3,235,940.00000.00240.68169.0000AID34006
Adenosine receptor A2aRattus norvegicus (Norway rat)IC50 (µMol)3,235,940.00000.00120.48289.0000AID34006
Adenosine kinaseHomo sapiens (human)IC50 (µMol)1,616,107.65500.00050.605210.0000AID33985; AID33990; AID33993; AID34006
Histone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)IC50 (µMol)44.00000.00010.51357.0000AID1636908
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, RIO-type serine/threonine-protein kinase Rio1Archaeoglobus fulgidusKd0.04000.04000.04000.0400AID977611
Heat shock cognate 71 kDa proteinHomo sapiens (human)Kd90.60060.26003.05117.0000AID1310291
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2, isoform CRA_aHomo sapiens (human)EC50 (µMol)91.16103.38103.38103.3810AID686991
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cyclin-dependent kinase 5, regulatory subunit 1 (p35)Homo sapiens (human)AC505.58500.01009.095533.0300AID504545
CDK5Homo sapiens (human)AC505.58500.01009.095533.0300AID504545
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (69)

Processvia Protein(s)Taxonomy
G1/S transition of mitotic cell cycleHeat shock cognate 71 kDa proteinHomo sapiens (human)
mRNA splicing, via spliceosomeHeat shock cognate 71 kDa proteinHomo sapiens (human)
kidney developmentHeat shock cognate 71 kDa proteinHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHeat shock cognate 71 kDa proteinHomo sapiens (human)
protein foldingHeat shock cognate 71 kDa proteinHomo sapiens (human)
protein import into nucleusHeat shock cognate 71 kDa proteinHomo sapiens (human)
response to unfolded proteinHeat shock cognate 71 kDa proteinHomo sapiens (human)
skeletal muscle tissue developmentHeat shock cognate 71 kDa proteinHomo sapiens (human)
cellular response to starvationHeat shock cognate 71 kDa proteinHomo sapiens (human)
response to xenobiotic stimulusHeat shock cognate 71 kDa proteinHomo sapiens (human)
response to nickel cationHeat shock cognate 71 kDa proteinHomo sapiens (human)
negative regulation of cardiac muscle cell apoptotic processHeat shock cognate 71 kDa proteinHomo sapiens (human)
response to activityHeat shock cognate 71 kDa proteinHomo sapiens (human)
synaptic vesicle uncoatingHeat shock cognate 71 kDa proteinHomo sapiens (human)
cerebellum developmentHeat shock cognate 71 kDa proteinHomo sapiens (human)
forebrain developmentHeat shock cognate 71 kDa proteinHomo sapiens (human)
regulation of protein stabilityHeat shock cognate 71 kDa proteinHomo sapiens (human)
response to estradiolHeat shock cognate 71 kDa proteinHomo sapiens (human)
response to progesteroneHeat shock cognate 71 kDa proteinHomo sapiens (human)
cellular response to heatHeat shock cognate 71 kDa proteinHomo sapiens (human)
protein refoldingHeat shock cognate 71 kDa proteinHomo sapiens (human)
regulation of protein-containing complex assemblyHeat shock cognate 71 kDa proteinHomo sapiens (human)
protein transmembrane import into intracellular organelleHeat shock cognate 71 kDa proteinHomo sapiens (human)
positive regulation by host of viral genome replicationHeat shock cognate 71 kDa proteinHomo sapiens (human)
estrous cycleHeat shock cognate 71 kDa proteinHomo sapiens (human)
response to ethanolHeat shock cognate 71 kDa proteinHomo sapiens (human)
positive regulation of proteolysisHeat shock cognate 71 kDa proteinHomo sapiens (human)
negative regulation of DNA-templated transcriptionHeat shock cognate 71 kDa proteinHomo sapiens (human)
ATP metabolic processHeat shock cognate 71 kDa proteinHomo sapiens (human)
positive regulation of mRNA splicing, via spliceosomeHeat shock cognate 71 kDa proteinHomo sapiens (human)
positive regulation of phagocytosisHeat shock cognate 71 kDa proteinHomo sapiens (human)
regulation of cell cycleHeat shock cognate 71 kDa proteinHomo sapiens (human)
membrane organizationHeat shock cognate 71 kDa proteinHomo sapiens (human)
regulation of protein complex stabilityHeat shock cognate 71 kDa proteinHomo sapiens (human)
chaperone-mediated autophagyHeat shock cognate 71 kDa proteinHomo sapiens (human)
late endosomal microautophagyHeat shock cognate 71 kDa proteinHomo sapiens (human)
protein targeting to lysosome involved in chaperone-mediated autophagyHeat shock cognate 71 kDa proteinHomo sapiens (human)
cellular response to hydrogen peroxideHeat shock cognate 71 kDa proteinHomo sapiens (human)
cellular response to cadmium ionHeat shock cognate 71 kDa proteinHomo sapiens (human)
cellular response to steroid hormone stimulusHeat shock cognate 71 kDa proteinHomo sapiens (human)
clathrin coat disassemblyHeat shock cognate 71 kDa proteinHomo sapiens (human)
positive regulation of lysosomal membrane permeabilityHeat shock cognate 71 kDa proteinHomo sapiens (human)
maintenance of postsynaptic specialization structureHeat shock cognate 71 kDa proteinHomo sapiens (human)
regulation of postsynapse organizationHeat shock cognate 71 kDa proteinHomo sapiens (human)
negative regulation of NLRP3 inflammasome complex assemblyHeat shock cognate 71 kDa proteinHomo sapiens (human)
negative regulation of supramolecular fiber organizationHeat shock cognate 71 kDa proteinHomo sapiens (human)
regulation of protein importHeat shock cognate 71 kDa proteinHomo sapiens (human)
positive regulation of protein refoldingHeat shock cognate 71 kDa proteinHomo sapiens (human)
chaperone-mediated autophagy translocation complex disassemblyHeat shock cognate 71 kDa proteinHomo sapiens (human)
slow axonal transportHeat shock cognate 71 kDa proteinHomo sapiens (human)
response to odorantHeat shock cognate 71 kDa proteinHomo sapiens (human)
chaperone cofactor-dependent protein refoldingHeat shock cognate 71 kDa proteinHomo sapiens (human)
purine ribonucleoside salvageAdenosine kinaseHomo sapiens (human)
dATP biosynthetic processAdenosine kinaseHomo sapiens (human)
ribonucleoside monophosphate biosynthetic processAdenosine kinaseHomo sapiens (human)
GMP salvageAdenosine kinaseHomo sapiens (human)
AMP salvageAdenosine kinaseHomo sapiens (human)
dAMP salvageAdenosine kinaseHomo sapiens (human)
purine nucleobase metabolic processAdenosine kinaseHomo sapiens (human)
positive regulation of cell population proliferationHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
gene expressionHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
heterochromatin formationHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
telomere organizationHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
methylationHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
regulation of receptor signaling pathway via JAK-STATHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
regulation of transcription regulatory region DNA bindingHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
DNA repairHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
DNA damage checkpoint signalingHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
G protein-coupled receptor bindingHeat shock cognate 71 kDa proteinHomo sapiens (human)
phosphatidylserine bindingHeat shock cognate 71 kDa proteinHomo sapiens (human)
RNA bindingHeat shock cognate 71 kDa proteinHomo sapiens (human)
protein bindingHeat shock cognate 71 kDa proteinHomo sapiens (human)
ATP bindingHeat shock cognate 71 kDa proteinHomo sapiens (human)
ATP hydrolysis activityHeat shock cognate 71 kDa proteinHomo sapiens (human)
enzyme bindingHeat shock cognate 71 kDa proteinHomo sapiens (human)
MHC class II protein complex bindingHeat shock cognate 71 kDa proteinHomo sapiens (human)
protein-macromolecule adaptor activityHeat shock cognate 71 kDa proteinHomo sapiens (human)
heat shock protein bindingHeat shock cognate 71 kDa proteinHomo sapiens (human)
ubiquitin protein ligase bindingHeat shock cognate 71 kDa proteinHomo sapiens (human)
A1 adenosine receptor bindingHeat shock cognate 71 kDa proteinHomo sapiens (human)
peptide bindingHeat shock cognate 71 kDa proteinHomo sapiens (human)
ADP bindingHeat shock cognate 71 kDa proteinHomo sapiens (human)
cadherin bindingHeat shock cognate 71 kDa proteinHomo sapiens (human)
unfolded protein bindingHeat shock cognate 71 kDa proteinHomo sapiens (human)
protein-folding chaperone bindingHeat shock cognate 71 kDa proteinHomo sapiens (human)
C3HC4-type RING finger domain bindingHeat shock cognate 71 kDa proteinHomo sapiens (human)
ATP-dependent protein disaggregase activityHeat shock cognate 71 kDa proteinHomo sapiens (human)
protein carrier chaperoneHeat shock cognate 71 kDa proteinHomo sapiens (human)
ATP-dependent protein folding chaperoneHeat shock cognate 71 kDa proteinHomo sapiens (human)
prostaglandin bindingHeat shock cognate 71 kDa proteinHomo sapiens (human)
clathrin-uncoating ATPase activityHeat shock cognate 71 kDa proteinHomo sapiens (human)
protein folding chaperoneHeat shock cognate 71 kDa proteinHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
RNA bindingAdenosine kinaseHomo sapiens (human)
deoxyadenosine kinase activityAdenosine kinaseHomo sapiens (human)
ATP bindingAdenosine kinaseHomo sapiens (human)
metal ion bindingAdenosine kinaseHomo sapiens (human)
adenosine kinase activityAdenosine kinaseHomo sapiens (human)
nucleic acid bindingHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
DNA bindingHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
protein bindingHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
histone methyltransferase activityHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
histone H3 methyltransferase activityHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
histone H3K79 trimethyltransferase activityHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
histone H3K79 methyltransferase activityHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (46)

Processvia Protein(s)Taxonomy
lysosomal membraneHeat shock cognate 71 kDa proteinHomo sapiens (human)
Prp19 complexHeat shock cognate 71 kDa proteinHomo sapiens (human)
photoreceptor inner segmentHeat shock cognate 71 kDa proteinHomo sapiens (human)
extracellular regionHeat shock cognate 71 kDa proteinHomo sapiens (human)
extracellular spaceHeat shock cognate 71 kDa proteinHomo sapiens (human)
nucleusHeat shock cognate 71 kDa proteinHomo sapiens (human)
nucleoplasmHeat shock cognate 71 kDa proteinHomo sapiens (human)
spliceosomal complexHeat shock cognate 71 kDa proteinHomo sapiens (human)
nucleolusHeat shock cognate 71 kDa proteinHomo sapiens (human)
lysosomal membraneHeat shock cognate 71 kDa proteinHomo sapiens (human)
late endosomeHeat shock cognate 71 kDa proteinHomo sapiens (human)
autophagosomeHeat shock cognate 71 kDa proteinHomo sapiens (human)
cytosolHeat shock cognate 71 kDa proteinHomo sapiens (human)
microtubuleHeat shock cognate 71 kDa proteinHomo sapiens (human)
intermediate filamentHeat shock cognate 71 kDa proteinHomo sapiens (human)
plasma membraneHeat shock cognate 71 kDa proteinHomo sapiens (human)
focal adhesionHeat shock cognate 71 kDa proteinHomo sapiens (human)
synaptic vesicleHeat shock cognate 71 kDa proteinHomo sapiens (human)
cell surfaceHeat shock cognate 71 kDa proteinHomo sapiens (human)
postsynaptic densityHeat shock cognate 71 kDa proteinHomo sapiens (human)
membraneHeat shock cognate 71 kDa proteinHomo sapiens (human)
secretory granule lumenHeat shock cognate 71 kDa proteinHomo sapiens (human)
melanosomeHeat shock cognate 71 kDa proteinHomo sapiens (human)
terminal boutonHeat shock cognate 71 kDa proteinHomo sapiens (human)
dendritic spineHeat shock cognate 71 kDa proteinHomo sapiens (human)
dendritic shaftHeat shock cognate 71 kDa proteinHomo sapiens (human)
lysosomal lumenHeat shock cognate 71 kDa proteinHomo sapiens (human)
perikaryonHeat shock cognate 71 kDa proteinHomo sapiens (human)
perinuclear region of cytoplasmHeat shock cognate 71 kDa proteinHomo sapiens (human)
clathrin-sculpted gamma-aminobutyric acid transport vesicle membraneHeat shock cognate 71 kDa proteinHomo sapiens (human)
extracellular exosomeHeat shock cognate 71 kDa proteinHomo sapiens (human)
blood microparticleHeat shock cognate 71 kDa proteinHomo sapiens (human)
lumenal side of lysosomal membraneHeat shock cognate 71 kDa proteinHomo sapiens (human)
photoreceptor ribbon synapseHeat shock cognate 71 kDa proteinHomo sapiens (human)
glycinergic synapseHeat shock cognate 71 kDa proteinHomo sapiens (human)
glutamatergic synapseHeat shock cognate 71 kDa proteinHomo sapiens (human)
presynaptic cytosolHeat shock cognate 71 kDa proteinHomo sapiens (human)
postsynaptic cytosolHeat shock cognate 71 kDa proteinHomo sapiens (human)
postsynaptic specialization membraneHeat shock cognate 71 kDa proteinHomo sapiens (human)
ficolin-1-rich granule lumenHeat shock cognate 71 kDa proteinHomo sapiens (human)
lysosomal matrixHeat shock cognate 71 kDa proteinHomo sapiens (human)
protein folding chaperone complexHeat shock cognate 71 kDa proteinHomo sapiens (human)
ribonucleoprotein complexHeat shock cognate 71 kDa proteinHomo sapiens (human)
cytosolHeat shock cognate 71 kDa proteinHomo sapiens (human)
plasma membraneHeat shock cognate 71 kDa proteinHomo sapiens (human)
cytoplasmHeat shock cognate 71 kDa proteinHomo sapiens (human)
nucleusHeat shock cognate 71 kDa proteinHomo sapiens (human)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
nucleoplasmAdenosine kinaseHomo sapiens (human)
cytosolAdenosine kinaseHomo sapiens (human)
plasma membraneAdenosine kinaseHomo sapiens (human)
nucleusAdenosine kinaseHomo sapiens (human)
cytosolAdenosine kinaseHomo sapiens (human)
nucleusHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
nucleoplasmHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
cytoplasmHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
intracellular membrane-bounded organelleHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
protein-containing complexHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
nucleusHistone-lysine N-methyltransferase, H3 lysine-79 specificHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (90)

Assay IDTitleYearJournalArticle
AID39867Cytotoxicity that caused a 50% reduction in absorbance at 490 nm in B16 mouse melanoma cells using MTS assay.2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Synthesis and cytotoxicity of 4-amino-5-oxopyrido[2,3-d]pyrimidine nucleosides.
AID84959Concentration required to reduce HSV-2 (G) induced cytopathogenicity by 50% in primary rabbit kidney cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID229230Concentration required to reduce vesicular stomatitis virus induced cytopathogenicity by 50% in HeLa cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID86057Antiviral activity against herpes simplex virus type 1(HSV-1) ELISA method1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Synthesis and evaluation of certain thiosangivamycin analogs as potential inhibitors of cell proliferation and human cytomegalovirus.
AID217479Minimum inhibitory concentration required to reduce vesicular stomatitis virus (VSV) induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID96382Tested in vitro for cytotoxicity against the human neoplastic cell line (KB cells).1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Arabinofuranosylpyrrolo[2,3-d]pyrimidines as potential agents for human cytomegalovirus infections.
AID42129Tested in vitro for cytotoxicity against the monkey kidney cells (BSC-1 cells).1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Arabinofuranosylpyrrolo[2,3-d]pyrimidines as potential agents for human cytomegalovirus infections.
AID338748Inhibition of phosphatidylinositol 4-kinase in human A431 cell membrane by liquid scintillation counting
AID167151Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in primary rabbit kidney cells1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID81930Visual cytotoxicity scored on HFF cells at the time of HCMV plaque enumeration.1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Synthesis and evaluation of certain thiosangivamycin analogs as potential inhibitors of cell proliferation and human cytomegalovirus.
AID1310291Binding affinity to human truncated HSC70 NBD (1 to 381 residues) by SPR analysis2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Exploiting Protein Conformational Change to Optimize Adenosine-Derived Inhibitors of HSP70.
AID217836Minimum inhibitory concentration required to reduce vaccinia virus(VV) induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID95827Cytotoxic activity tested against exponentially growing KB cells, determined by staining method1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and ++thiosangivamycin: influence of various 7-substituents on antiviral activity.
AID82054Cytotoxicity against HFF cells, estimated by visual scoring of cells not affected by virus infection in the plaque reduction assay1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and ++thiosangivamycin: influence of various 7-substituents on antiviral activity.
AID33985Inhibition of recombinant human adenosine kinase2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues.
AID87203Tested in vitro for antiviral activity against HSV-1 in plaque reduction assay.1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Arabinofuranosylpyrrolo[2,3-d]pyrimidines as potential agents for human cytomegalovirus infections.
AID87304Concentration required to cause a microscopically detectable alteration in cell morphology in HeLa cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID98334In vitro cytotoxicity was evaluated against the L1210 Murine leukemic cells1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Synthesis, cytotoxicity, and antiviral activity of some acyclic analogues of the pyrrolo[2,3-d]pyrimidine nucleoside antibiotics tubercidin, toyocamycin, and sangivamycin.
AID225769Concentration required to reduce polio virus type 1 induced cytopathogenicity by 50% in HeLa cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID82422Tested in vitro for cytotoxicity against the normal human diploid cells (HFF cells).1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Arabinofuranosylpyrrolo[2,3-d]pyrimidines as potential agents for human cytomegalovirus infections.
AID226343Concentration required to reduce sindbis virus induced cytopathogenicity by 50% in vero cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID167327Concentration required to cause a microscopically detectable alteration in cell morphology in primary rabbit kidney cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID220035Concentration required to reduce coxsackie virus 4 induced cytopathogenicity by 50% in HeLa cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID90778In vitro antiviral activity against human cytomegalovirus by plaque method.1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Synthesis and evaluation of certain thiosangivamycin analogs as potential inhibitors of cell proliferation and human cytomegalovirus.
AID337262Antifungal activity against Candida albicans at 1.25 mg/6.4 mm disk
AID54506Minimum inhibitory concentration required to reduce Coxsackie virus type B-4-induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID95683In vitro inhibition of KB cell proliferation.1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Synthesis and evaluation of certain thiosangivamycin analogs as potential inhibitors of cell proliferation and human cytomegalovirus.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID90934In vitro antiviral activity against human cytomegalovirus by yield reduction assay.1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Synthesis and evaluation of certain thiosangivamycin analogs as potential inhibitors of cell proliferation and human cytomegalovirus.
AID34006Concentration required for 50% inhibition of the adenosine kinase (AK) activity.2004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
A TOPS-MODE approach to predict adenosine kinase inhibition.
AID98370Inhibition of L1210 murine leukemic cells proliferation in vitro1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Synthesis and evaluation of certain thiosangivamycin analogs as potential inhibitors of cell proliferation and human cytomegalovirus.
AID228410Concentration required to reduce reovirus type 1 induced cytopathogenicity by 50% in vero cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID84611Minimum inhibitory concentration required to reduce Herpes simplex virus type 2 (HSV-2 strain G) induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID229022Concentration required to reduce vaccinia virus induced cytopathogenicity by 50% in primary rabbit kidney cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID82404Cytotoxicity was evaluated against the Human diploid cells (HFF)1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Synthesis, cytotoxicity, and antiviral activity of some acyclic analogues of the pyrrolo[2,3-d]pyrimidine nucleoside antibiotics tubercidin, toyocamycin, and sangivamycin.
AID90773Antiviral activity against Human Cytomegalovirus (HCMV) replication in a plaque reduction assay1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and ++thiosangivamycin: influence of various 7-substituents on antiviral activity.
AID229059Concentration required to cause a microscopically detectable alteration in cell morphology in vero cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID33990Inhibition of human adenosine kinase activity2002Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6
QSAR study on adenosine kinase inhibition of pyrrolo[2,3-d]pyrimidine nucleoside analogues using the hansch approach.
AID87798Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in Hela cells1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID85570Minimum inhibitory concentration required to reduce Herpes simplex virus type 1 (HSV-1, strain KOS) induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID96612Minimum inhibitory concentration required to reduce incorporation of [5-3H]-Urd into TCA-insoluble material from murine leukemia L1210 cells1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID318601Cytotoxicity against mouse P388 cells assessed as concentration required for 50% inhibition2008Journal of natural products, Mar, Volume: 71, Issue:3
Antineoplastic agents. 536. New sources of naturally occurring cancer cell growth inhibitors from marine organisms, terrestrial plants, and microorganisms(1a,).
AID162251Minimum inhibitory concentration required to reduce Polio virus type 1 induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID204956Minimum inhibitory concentration required to reduce sindbis virus induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID87204Tested in vitro for antiviral activity against HSV-1 in yield reduction assay.1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Arabinofuranosylpyrrolo[2,3-d]pyrimidines as potential agents for human cytomegalovirus infections.
AID96660Dose required to inhibit proliferation of L-1210 Cells by 50%1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID337263Cytotoxicity against mouse L1210 cells
AID1636908Inhibition of DOT1L (unknown origin) using chicken nucleosome as substrate in presence of [3H]SAM incubated for 1 hr by TopCount method2016Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18
New small molecule inhibitors of histone methyl transferase DOT1L with a nitrile as a non-traditional replacement for heavy halogen atoms.
AID220038Concentration required to reduce coxsackie virus B4 induced cytopathogenicity by 50% in vero cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID155586Minimum inhibitory concentration required to reduce parainfluenza type 3 induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID218065Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in Vero cells1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID90937Tested in vitro for antiviral activity against human cytomegalovirus (HCMV) in yield reduction assay.1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Arabinofuranosylpyrrolo[2,3-d]pyrimidines as potential agents for human cytomegalovirus infections.
AID96611Minimum inhibitory concentration required to reduce incorporation of [4,5-3H]leucine into TCA-insoluble material from murine leukemia L1210 cells1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID33993Inhibition concentration against human adenosine kinase2002Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6
QSAR study on adenosine kinase inhibition of pyrrolo[2,3-d]pyrimidine nucleoside analogues using the hansch approach.
AID1296049Induction of phenotypic perturbation in human ONS cells assessed as decrease in autophagy markers level in at 10 uM after 24 hrs relative to control2016Journal of natural products, Feb-26, Volume: 79, Issue:2
A Grand Challenge: Unbiased Phenotypic Function of Metabolites from Jaspis splendens against Parkinson's Disease.
AID79951Antiviral activity of the compound was evaluated against the Human cytomegalo virus (HCMV)1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Synthesis, cytotoxicity, and antiviral activity of some acyclic analogues of the pyrrolo[2,3-d]pyrimidine nucleoside antibiotics tubercidin, toyocamycin, and sangivamycin.
AID90794Tested in vitro for antiviral activity against human cytomegalovirus (HCMV) in plaque reduction assay.1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Arabinofuranosylpyrrolo[2,3-d]pyrimidines as potential agents for human cytomegalovirus infections.
AID229232Concentration required to reduce vesicular stomatitis virus induced cytopathogenicity by 50% in primary rabbit kidney cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID392502Antiviral activity against Herpes simplex virus2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID83889Concentration required to reduce HSV-1 (KOS) induced cytopathogenicity by 50% in primary rabbit kidney cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID1296048Induction of phenotypic perturbation in human ONS cells assessed as decrease in EEA1-associated early endosomes level in at 10 uM after 24 hrs by EEA1 staining based assay relative to control2016Journal of natural products, Feb-26, Volume: 79, Issue:2
A Grand Challenge: Unbiased Phenotypic Function of Metabolites from Jaspis splendens against Parkinson's Disease.
AID199168Minimum inhibitory concentration required to reduce reo virus type 1 induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID382097Inhibition of adenosine kinase2008Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9
A CoMSIA study on the adenosine kinase inhibition of pyrrolo[2,3-d]pyrimidine nucleoside analogues.
AID96613Minimum inhibitory concentration required to reduce incorporation of [methyl-3H]dThd into TCA-insoluble material from murine leukemia L1210 cells1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID143811Cytotoxicity that caused a 50% reduction in absorbance at 490 nm in normal human fibroblast (NHF) cells using MTS assay.2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Synthesis and cytotoxicity of 4-amino-5-oxopyrido[2,3-d]pyrimidine nucleosides.
AID84641Cytotoxicity that caused a 50% reduction in absorbance at 490 nm in human prostate cancer HTB-81 cells using MTS assay.2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Synthesis and cytotoxicity of 4-amino-5-oxopyrido[2,3-d]pyrimidine nucleosides.
AID224918Concentration required to reduce parainfluenza virus type 3 induced cytopathogenicity by 50% in vero cell cultures.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Antiviral activity of C-5 substituted tubercidin analogues.
AID217478Minimum inhibitory concentration required to reduce Vesicular stomatitis virus (VSV) induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID96608Inhibition of murine leukemia L1210 cell growth1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID96052Cytotoxicity was evaluated in Human neoplastic cell line (KB)1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Synthesis, cytotoxicity, and antiviral activity of some acyclic analogues of the pyrrolo[2,3-d]pyrimidine nucleoside antibiotics tubercidin, toyocamycin, and sangivamycin.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2012PloS one, , Volume: 7, Issue:5
Interaction of Rio1 kinase with toyocamycin reveals a conformational switch that controls oligomeric state and catalytic activity.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745847CMV-Luciferase Counterscreen for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745849Viability Counterscreen for CMV-Luciferase Assay of Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745850Viability Counterscreen for Confirmatory qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745848Confirmatory qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (129)

TimeframeStudies, This Drug (%)All Drugs %
pre-199051 (39.53)18.7374
1990's16 (12.40)18.2507
2000's27 (20.93)29.6817
2010's30 (23.26)24.3611
2020's5 (3.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.82 (24.57)
Research Supply Index4.88 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews6 (4.62%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other124 (95.38%)84.16%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]